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ABSTRACT
Activated Leukocyte Cell Adhesion Molecule (ALCAM) has been linked to the 
progression of numerous human cancers, where it appears to play a complex role. 
The current study aims to further assess the importance of ALCAM in prostate cancer 
and the prognostic potential of serum ALCAM as a biomarker for prostate cancer 
progression. Here we demonstrate enhanced levels of tissue ALCAM are associated 
with metastasis. Additionally, elevated serum ALCAM is indicative of progression 
and poorer patient outlook, and demonstrates comparable prognostic ability to PSA 
in terms of metastasis and prostate cancer survival. ALCAM suppression enhanced 
proliferation and invasiveness in PC-3 cells and motility/migration in PC-3 and 
LNCaP cells. ALCAM suppressed PC-3 cells were generally less responsive to HGF 
and displayed reduced MET transcript expression. Furthermore a recombinant human 
ALCAM-Fc chimera was able to inhibit LNCaP cell attachment to HECV and hFOB1.19 
cells. Taken together, ALCAM appears to be a promising biomarker for prostate cancer 
progression, with enhanced serum expression associated with poorer prognosis. 
Suppression of ALCAM appears to impact cell function and cellular responsiveness to 
certain micro environmental factors.
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INTRODUCTION
Dissemination and metastatic spread of cancer 
cells is a key determinant of patient prognosis and 
the bone is a common site for metastasis arising from 
prostate cancer [1]. Additional research is required 
to fully comprehend the molecular and cellular 
mechanisms involved in these processes and to develop 
new therapeutic strategies.
Activated leukocyte cell adhesion molecule 
(ALCAM, CD166) was initially characterized by Bowen 
et al. in 1995 [2]. ALCAM, a transmembrane glycoprotein, 
is a member of the immunoglobulin superfamily and 
has been identified as mediating homophilic, ALCAM-
ALCAM, and heterophilic, ALCAM-CD6, interactions 
[2, 3]. ALCAM has been identified as a substrate of a 
disintegrin and metalloprotease (ADAM) 17 and can 
be shed from the cellular surface, a process that can 
be enhanced by epidermal growth factor (EGF) and 
transforming growth factor (TGF) β [4–6]. ALCAM has 
been implicated to influence cellular traits associated 
with cancer progression in vitro and in vivo [6–11], 
though there is some conflict within the literature. 
Alterations in ALCAM expression have been reported and 
associated with the progression or prognosis of various 
human cancers including, breast [7, 12–15], melanoma 
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[16, 17] and gastric [18, 19] cancer, however there are 
again contrasting reports within the literature.
Accumulating evidence suggests that ALCAM may 
play a role in cancer cell dissemination and development 
within the bone environment. Early work has demonstrated 
reduced ALCAM levels in breast cancer patients who 
developed skeletal metastasis [14]. Additional studies 
exploring the prognostic role of ALCAM in breast 
cancer dissemination have implicated over-expression 
of ALCAM with nodal involvement and a tendency 
toward increased tumor cell presence in the bone marrow 
[7]. Hansen et al., have explored the role of ALCAM in 
prostate cancer [6]. Using a number of in vivo models they 
demonstrated that ALCAM suppression does not impact 
on growth or local invasion of cancer cells inoculated into 
the prostate but significantly reduced skeletal metastasis 
and burden following intracardiac inoculation and resulted 
in reduced growth and survival of intratibially inoculated 
cells [6].
The current study aims to further explore the 
functional role of ALCAM in regulating aggressive 
traits in prostate cancer cells and their responsiveness 
to environmental factors, together with assessing the 
potential of serum ALCAM as a marker of prostate cancer 
progression.
RESULTS
Clinical significance of ALCAM in prostate 
cancer tissues and serum
ALCAM expression was examined in a tissue 
microarray (TMA) containing core biopsies of localized, 
metastatic disease and paired normal tissues. ALCAM 
expression was observed mainly in epithelial tissues 
at both cytoplasmic and membranous locations, 
though differential staining profiles of cytoplasmic 
and membranous ALCAM were not performed in the 
current analysis. Enhanced ALCAM staining intensity 
was observed in cancerous compared to normal samples, 
though this was not statistically significant (p = 0.32; 
Figure 1A and 1C). Significantly enhanced ALCAM 
staining was observed in M1 compared to M0 patients 
(p = 0.027; Figure 1B and 1D), though no significant 
differences were seen between stage (p = 0.161; Figure 
1E), Gleason score (p = 0.150; Figure 1F) or patient 
prostate specific antigen (PSA) levels (p = 0.668; Figure 
1G). Furthermore, comparison of paired normal and 
cancer tissues (n = 8 pairs, Supplementary Figure 1), 
highlighted enhanced staining in cancer tissues in 6 (75%) 
of the pairs.
The prognostic potential of serum ALCAM was 
also assessed in 229 prostate cancer patients (Figure 2). 
Significantly higher levels of ALCAM were observed in 
patients who died of prostate cancer (PRCa) compared 
to those who were still alive (Figure 2A, p < 0.001) and 
in M1 patients compared to M0 patients (Figure 2B, 
p = 0.002), with borderline significant elevations observed 
in N1 compared to N0 patients (Figure 2C, p = 0.05). 
Significant differences in ALCAM serum levels were 
observed between Gleason score groups (Figure 2D). 
Post hoc analysis revealed significantly elevated ALCAM 
serum levels in Gleason 9 compared to Gleason 7 or 
Gleason 6 samples, and in Gleason 8 compared to Gleason 
7 or Gleason 6 samples (all p < 0.05). No significant 
differences were seen between Gleason 10 and other 
groups, potentially due to the smaller sample size of this 
group. Significant differences were also detected between 
T score (Figure 2E) and PSA level (Figure 2F). Post hoc 
analysis indicated significantly higher serum ALCAM 
levels in T4 patients compared to either T3 or a combined 
T1-2 classification group and in T3 compared to T1-2 
samples (all p < 0.05) (Figure 2E). Additionally, post hoc 
analysis indicated significantly elevated serum ALCAM 
in patients with a PSA level > 50 ng/ml in comparison 
to those whose PSA < 10 ng/ml and whose PSA was 
between 10.1 and 50 ng/ml (both p < 0.05) (Figure 2F). 
A positive correlation was also noted between serum PSA 
and ALCAM levels, where clinical PSA information was 
available, (n = 217, Spearman Rank correlation coefficient 
= 0.275, p ≤ 0.001, data not shown).
Receiver operating characteristic (ROC) analysis 
was undertaken to explore the prognostic capacity of 
serum ALCAM, compared to PSA, to identify patients who 
died of PRCa (Figure 2G) or with metastasis (Figure 2H). 
Combined ALCAM and PSA serum levels were available 
for 196 patients with survival outcomes (alive, n = 183; 
died of PRCa, n = 13) and 51 patient with M scores 
(M0, n = 45; M1, n = 6). Serum ALCAM proved to have 
comparable diagnostic power to PSA, performing slightly 
better at identifying those patients who died of PRCa 
(ALCAM AUC = 0.80, 95% CI 0.69 – 0.91 compared to 
PSA AUC = 0.71, 95% CI 0.51 – 0.91) (Figure 2G) and 
slightly worse at identifying those patients with metastasis 
(ALCAM AUC = 0.88, 95% CI 0.78 – 0.99 vs. PSA AUC 
= 0.95, 95% CI 0.88 – 1.02) (Figure 2H).
Generation and verification of ALCAM 
suppression in PC-3 and LNCaP prostate cancer 
lines
ALCAM transcript expression was screened in a 
number of human prostate, prostate cancer, osteoblast 
(hFOB1.19) and endothelial (HECV) cell lines (Figure 
3A). With the exception of the MDA-PCa-2b cell line, 
ALCAM was expressed at moderate to strong levels. PC-3 
and LNCaP cell lines were chosen for transfection with 
either pEF6 control plasmids or pEF6 plasmids containing 
ribozyme transgenes targeting ALCAM. Quantitative 
transcript analysis revealed a significant decrease in 
ALCAM expression, compared to control cells, in PC-3 
cells (p = 0.021) and LNCaP cells (p = 0.049) following 
Oncotarget6364www.oncotarget.com
transfection with the ALCAM ribozyme transgene (Figure 
3B and 3C). Similarly, western blot analysis indicated a 
suppression of ALCAM protein in both PC-3 and LNCaP 
cells transfected with the ALCAM ribozyme transgene 
(Figure 3D and 3E).
Functional characterization of ALCAM 
suppression and impact on cellular 
responsiveness to a bone-like environment
Functional characterization of ALCAM suppressed 
cells was undertaken in conjunction with 50 µg/ml 
bone matrix extract (BME) intended to mimic a bone 
like environment in vitro (Figure 4). Knockdown of 
ALCAM in untreated PC-3 cells significantly enhanced 
PC-3 cell growth rates over a 5 day incubation period 
(p = 0.04) but had no significant effect on the LNCaP 
cell line. BME treatment had no significant impact on the 
growth of either cell line (Figure 4A and 4B). ALCAM 
knockdown in untreated cells did not significantly impact 
on the cell-matrix adhesion of either PC-3 (Figure 4C) 
or LNCaP cells (Figure 4D), though general reductions 
were observed in both cell lines. No significant effects 
were noted following treatment of either line with BME, 
Figure 1: ALCAM tissue expression in a tissue microarray of prostate and prostate cancer tissues. Representative images of normal 
and cancerous cores (A) and cores derived from M0 and M1 patients (B) shown at ×4 and ×20 objective magnifications. Median staining 
intensity scores are presented for normal and cancerous tissue (C), M0 and M1 patients (D), patient stage (E), Gleason score (F) and PSA 
score (G). Boxplot data represents the median, Q1 and Q3 staining intensity scores and whiskers represent minimum and maximum values. 
*Represents p < 0.05.
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though generally a greater response was seen in PC-3ALCAM 
KO cells compared to PC-3pEF6 cells. ALCAM knockdown 
also significantly enhanced cellular invasiveness in 
untreated PC-3 cells (p = 0.009), and non-significantly 
enhanced LNCaP invasiveness (p = 0.427). Differential 
responses to BME treatment within PC-3 and LNCaP 
cells was again observed, although significance was 
not reached (Figure 4E and 4F). Motility bead analysis 
demonstrated enhanced motility in PC-3ALCAM KO cells 
compared to PC-3pEF6 control cells (p = 0.007, Figure 4G) 
and similarly, LNCaPALCAM KO cells were found to have 
enhanced, though non-significantly, 4 hour migratory 
rates compared to LNCaPpEF6 cells using an electric 
cell substrate impedance sensing (ECIS) based assay 
(p = 0.091; Figure 4H). In both cell lines, the addition of 
BME had no significant impact on motility.
Potential mechanistic impact of ALCAM 
suppression in prostate cancer cell lines
A protein microarray was used to identify potential 
differences between PC-3pEF6 and PC-3ALCAM KO cells. This 
highlighted differential expression and/or phosphorylation 
of certain receptors, including the hepatocyte growth factor 
Figure 2: Association of serum ALCAM expression with patient clinical pathological information and prognostic 
ability. Serum ALCAM levels were examined in a cohort of prostate cancer patients and correlated with available clinical pathological 
information. Elevated levels of serum ALCAM were observed in patients who died from prostate cancer (A), those with detectable 
metastasis (B) and those with nodal involvement (C). Higher serum ALCAM was also generally associated with higher Gleason score (D), 
T-score (E) and PSA level (F). ROC analysis demonstrated a comparable prognostic capacity of serum ALCAM and PSA to predict patients 
who died of prostate cancer (total n = 196 samples with PSA and ALCAM levels; alive, n = 183 and died of PRCa, n = 13) (G) and those 
with metastasis (total n = 51 samples with PSA and ALCAM levels; M0, n = 45 and M1, n = 6) (H). Box plots represent median, Q1 and 
Q3 data and whiskers represent minimum and maximum values. ***Represents p ≤ 0.001; **Represents p ≤ 0.01; and *Represents p < 0.05.
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(HGF) receptor MET, where a general decrease in signal 
intensity was observed in a number of pan and phospho-
specific probes (Figure 5A). Subsequently, quantification 
of MET transcript levels indicated a significant reduction 
in PC-3ALCAM KO compared to PC-3pEF6 cells (p = 0.01, 
Figure 5B). We also explored the responsiveness of PC-
3pEF6 and PC-3ALCAM KO cells to HGF. Data is presented 
as percentage change in either PC-3pEF6 or PC-3ALCAM 
KO following treatment with 40ng/ml HGF in relation 
to the relative untreated control to give an indication 
and comparison of the capacity of such cells to respond 
to HGF, with >100% indicating a positive and < 100% 
indicating an inhibitory response. PC-3ALCAM KO cells 
were generally found to have a lower capacity to respond 
to HGF than PC-3pEF6 cells in terms of 5 day growth (p 
= 0.067, Figure 5C), invasion (p = 0.094, Figure 5D) 
and motility (p = 0.126, Figure 5E). No significant 
differences were seen regarding cell-matrix adhesion 
(p = 0.537, Figure 5F). We further analyzed the expression 
profile of a number of other key molecules which may 
act downstream. Within the protein array, alterations were 
seen in a number of pan and phospho-specific AKT1 
antibodies (Supplementary Figure 2A), though both 
enhanced and decreased total expression was observed 
across different antibodies following ALCAM knockdown 
and subsequently, no significant difference in transcript 
expression was observed (p = 0.229; Supplementary 
Figure 2B) between PC-3pEF6 and PC-3ALCAM KO cells. 
Similarly expression profiles of total and phospho-specific 
expression of extracellular signal-regulated kinase (ERK) 1 
Figure 3: ALCAM expression and targeting in prostate cancer cell lines. RT-PCR demonstrating ALCAM transcript expression in 
the majority of human prostate cell lines, hFOB1.19 osteoblast and HECV endothelial cell lines (A). Quantitative PCR demonstrated 
that targeting of ALCAM significantly reduced transcript expression in the PC-3 cell line (n = 3) (B) and the LNCaP cell line (n = 3) 
(C). Western blot analysis demonstrating reduced protein levels following ALCAM targeting in the PC-3 (D) and LNCaP (E) cell lines. 
Composite gel/blot images show representative images, cropped for conciseness. Comparative bands and adjustments for each individual 
molecule were taken from the same image. Data represents mean percentage control values  ± SEM. *Represents p < 0.05.
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& 2 were explored in the protein microarray where general 
increases in total ERK1 expression and only minor changes 
in total ERK2 were observed (Supplementary Figure 2C) 
following ALCAM suppression, whereas no significant 
differences in the transcript expression of ERK1 (p = 0.520; 
Supplementary Figure 2D) but a significant decrease in 
ERK2 transcripts were observed (p < 0.001; Supplementary 
Figure 2E) in PC-3ALCAM KO compared to PC-3pEF6 cells. 
Interestingly, according to the micro-array, the greatest 
difference following ALCAM suppression, relative to 
the control, was an enhanced phosphorylation of ERK1/2 
Y204. Finally, the protein micro-array also demonstrated 
alterations in focal adhesion kinase (FAK) expression and 
phosphorylation following ALCAM suppression, with 
greatest reductions, relative to the control, seen in total 
FAK, FAK S732 and FAK S722 (Supplementary Figure 2F), 
Figure 4: Impact of ALCAM suppression and bone matrix extract (BME) on prostate cancer cell function. Cell growth in response 
to ALCAM knockdown and treatment with BME in PC-3 (n = 4) (A) and LNCaP (n = 4) (B) cell lines. Impact of ALCAM suppression and 
BME treatment on cell matrix adhesion in the PC-3 (n = 3) (C) and LNCaP (n = 4) (D) cell line. Impact of ALCAM suppression and BME 
treatment on cellular invasion in PC-3 (n = 3) (E) and LNCaP (n = 3) (F) cell lines. Cell motility bead assay demonstrating the response 
of PC-3 cells to ALCAM knockdown and BME treatment (n = 4) (G). Cell migration in the LNCaP cell line in response to ALCAM 
suppression and BME treatment following a 4 hour period, quantified using an ECIS based assay (n = 4) (H). Data represents mean values 
± SEM., ***Represents p ≤ 0.001, **Represents p ≤ 0.01 and *Represents p < 0.05.
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Figure 5: Mechanistic implications of ALCAM suppression and impact on responsiveness to hepatocyte growth factor (HGF). 
Protein microarray demonstrating signal expression profile of included MET and phospho-MET antibodies in PC-3 control and ALCAM 
knockdown cells (n = 1) (A). Quantitative PCR analysis of MET transcript expression in PC-3 control and ALCAM knockdown cells (n 
= 3) (B), quantitative PCR data shown represents mean percentage control ± SEM, ** represents p ≤ 0.01. Impact of HGF treatment on the 
responsiveness of PC-3 control or ALCAM knockdown cells on 5 day growth (n = 4) (C), invasion (n = 3) (D), motility (n = 4) (E) and 
matrix-adhesion (n = 3) (F). Data shown represents the mean percentage change ± SEM in comparison to the relative untreated control or 
ALCAM knockdown cells to demonstrate respective responsive rate to HGF in each individual line.
Oncotarget6369www.oncotarget.com
which is partially supported at the transcript level where 
ALCAM suppression led to a significant decrease in FAK 
expression (p = 0.002; Supplementary Figure 2G).
Impact of ALCAM-Fc chimera on endothelial 
attachment and function
The impact of an ALCAM-Fc chimera, containing 
Trp28-Ala526 of ALCAM, on prostate cancer cell 
attachment to HECV endothelial cells was explored. No 
tested concentration of ALCAM-Fc chimera significantly 
impacted on PC-3 (Figure 6A) or VCaP (Figure 6C) 
attachment to the HECV monolayer. However, significant 
differences were seen on LNCaP attachment (Figure 6B) 
with post hoc analysis indicating significant inhibition at 
0.5 µg/ml (p = 0.002), 1.5 µg/ml (p = 0.002) and 3.0 µg/ml 
(p < 0.001) concentrations compared to untreated control.
ALCAM-Fc chimera did not significantly influence 
HECV 5 day growth rates (Figure 6D) or cellular 
migration (Figure 6E) but significantly impacted on HECV 
tubule formation, with post hoc analysis highlighting 
significant increases at 0.5 µg/ml, 1.5 µg/ml and 3.0 µg/
ml concentrations (p = 0.005, 0.01 and 0.038, respectively, 
vs. untreated HECV cells) (Figure 6F). 
Impact of ALCAM-Fc chimera on osteoblast 
attachment
No significant alterations were seen in PC-3 or 
VCaP attachment to a hFOB1.19 osteoblast monolayer 
Figure 6: Impact of ALCAM-Fc chimera on cancer cell attachment and endothelial cell function. Effect of increasing concentrations 
of ALCAM-Fc chimera on PC-3 (A), LNCaP (B) and VCaP (C) cancer cell attachment to a HECV endothelial monolayer. Impact of 
increasing concentrations of ALCAM-Fc chimera on 5 day growth rates (D), 4 hour migration (E) and tubule formation (F) of HECV 
human endothelial cells. Change in resistance during an ECIS based wounding assay was taken as a surrogate of cellular migration. Effect 
of increasing concentrations of ALCAM-Fc chimera on PC-3 (G), LNCaP (H) and VCaP (I) cancer cell attachment to an hFOB1.19 
osteoblast monolayer. Data shown represents mean percentage control (n = 3) ± SEM. ***Represents p ≤ 0.001, **Represents p ≤ 0.01 and 
*Represents p < 0.05.
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at any ALCAM-Fc chimera concentration (Figure 6G 
and 6I), though generally higher numbers of PC-3 cells 
adhered at the 3.0 µg/ml concentration. Increasing 
concentrations of ALCAM-Fc chimera were found to 
significantly inhibit LNCaP attachment rates (Figure 6H), 
with post hoc analysis highlighting significant attachment 
inhibition at 3.0 µg/ml concentration (p = 0.007 vs. 
untreated control).
DISCUSSION
The cell adhesion molecule ALCAM has been 
recognized as an important molecule in cancer progression 
and metastasis though its precise role appears to be 
complex and remains to be fully elucidated. The current 
study aimed to further explore the relevance of ALCAM 
in prostate cancer cells and associated mechanisms, the 
potential of serum ALCAM to act as a biomarker of 
prostate cancer and the impact of an ALCAM-Fc chimera, 
containing extracellular regions of ALCAM, to influence 
other cell types involved in the metastatic cascade.
Several studies have looked at ALCAM 
immunostaining in prostate cancer. Kristiansen et al., 
highlighted a general up-regulation of ALCAM in tumor 
tissues, where enhanced expression was associated with 
low Gleason grade and a lower expression associated 
with higher grade disease [20]. A later study by this 
group supported ALCAM over-expression in prostate 
cancer samples and also demonstrated the potential of 
cytoplasmic, but not membranous, ALCAM to act as 
a prognostic marker of PSA relapse, highlighting the 
significance of protein location in addition to expression 
in cancer progression [21]. Further work, using a 
large scale tissue microarray format, noted ALCAM 
expression predominantly at the membrane with any 
cytoplasmic staining correlating with strong membranous 
expression and similarly associated high membranous 
ALCAM immunostaining to correlate with favorable 
tumor characteristics such as T stage, nodal status and 
preoperative PSA, with high ALCAM expression also 
linked to reduced risk of biochemical recurrence [22]. 
Differential expression of ALCAM has been observed in 
many other cancer types, where its cellular location again 
has been implicated as a significant factor. For example, 
in breast cancer reduced ALCAM transcript expression 
has been observed to associate with more aggressive 
phenotypes and poorer patient outlooks with reductions 
of either cytoplasmic and/or membranous ALCAM 
staining observed in patient tumor tissue and/or those 
with bone metastasis [13, 14]. Another study associated 
enhanced cytoplasmic ALCAM expression with reduced 
disease free survival rates, suggesting a role for strong 
cytoplasmic ALCAM expression as a marker of aggressive 
disease [15], whereas evaluation of membranous staining 
in a different study reported a link between decreased 
ALCAM expression and advanced tumor size, grade, 
negative estrogen and progesterone status and poorer 
survival rates, noting links between cytoplasmic staining 
and stronger membranous staining [12]. A further study, 
not differentiating between membranous and cytoplasmic 
staining, demonstrated the correlation of strong ALCAM 
expression with nodal involvement and presence of tumor 
cells in the bone marrow, with strong ALCAM expression 
in ductal carcinomas also correlating with reduced rates 
of recurrence free and overall survival [7]. In colorectal 
cancer, analysis of cytoplasmic and membranous ALCAM 
expression indicated a significant correlation between 
membranous ALCAM expression and reduced patient 
survival rates [23]. A different study noted predominant 
membranous ALCAM expression in colorectal samples, 
with cytoplasmic staining associated with strong 
membrane expression, and following the analysis of 
membranous ALCAM expression reported a significantly 
reduced overall survival rate in ALCAM negative 
patients [24]. Similar links to cellular localization have 
also been implicated in lung cancer, where membranous 
ALCAM expression, but not cytoplasmic, associated 
with shortened overall survival [25], oral squamous cell 
carcinomas (OSCCs) where cytoplasmic accumulation 
of ALCAM was indicative of poor patient prognosis 
[26] and pancreatic cancer, where cytoplasmic ALCAM 
expression in cancer cells was observed compared to 
membranous expression in normal cells and increased 
ALCAM expression was linked to adverse recurrence free 
and overall survival rates [27]. Taken together, ALCAM 
expression appears to be useful as a predictive prognosis 
tool, however, some contrast appears within the literature 
and its role may be dependent on cellular localization or 
cancer type. In our current study ALCAM staining levels 
were found to be generally enhanced in cancer tissues 
and were significantly associated with metastatic disease, 
though no significant associations were seen with other 
clinical pathological factors. However, the data presented 
here represents only a small microarray and no differential 
expression analysis was performed for membranous or 
cytoplasmic expression. Hence, these factors may account 
for discrepancies observed between the results presented 
here and other studies but again give an indication of the 
potential use for ALCAM staining as a prognostic factor.
Currently, there is very little information regarding 
the clinical relevance of serum ALCAM as a prognostic 
factor for prostate cancer progression. Previous mouse 
models utilizing human PC-3 and LNCaP xenografts 
have demonstrated a role for tumor, but not host derived 
ectodomain ALCAM in influencing the tumor burden 
of subcutaneous and orphotopic xenographs [6]. Within 
our cohort, significantly higher levels of serum ALCAM 
were associated with T stage, Gleason score and survival. 
ALCAM and PSA levels were also found to correlate and 
demonstrated comparable abilities to identify patients 
with metastasis and those who died of the disease, though 
serum ALCAM is not prostate specific and hence any 
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clinical benefit may be in conjunction with other markers. 
Numerous studies have explored serum ALCAM in other 
cancers types where elevated levels are indicative of 
cancer or of poorer prognosis in gastric cancer [18, 28], 
hepatocellular carcinoma [29] and esophageal cancer 
[30]. Similar observations have also been made in breast 
cancer, where studies have shown ALCAM to perform 
as well or better than cancer antigen 15-3 (CA15-3) 
and carcinoembryonic antigen (CEA) [31–33] and in 
epithelial ovarian cancer, where correlations between 
serum ALCAM and cancer antigen 125 (CA125) were 
noted [34]. However, other studies have also suggested 
either no difference between pancreatic cancer and 
chronic pancreatitis [35], or that enhanced serum ALCAM 
may be associated with moderate, compared to poorly 
differentiated cervical cancer [36]. Currently, PSA testing 
is widely used in diagnosis and monitoring of prostate 
cancer, though such a test carries both advantages and 
limitations and hence there is a need to identify, refine 
or develop new diagnostic and predictive assays for 
prostate cancer. Our study demonstrates the significance 
of serum ALCAM as a potential marker of prostate cancer 
progression, highlighting its use as a possible indicator of 
poor prognosis. Further work on larger cohorts of prostate 
cancer patients are needed to further realize the potential 
of serum ALCAM, potentially in conjunction with other 
markers, as a biomarker for prostate cancer and disease 
progression.
To further explore the wider implications and 
significance of extracellular ALCAM we explored the 
impact of an ALCAM-Fc chimera, including Trp28 
– Ala526 and representing extracellular regions of 
ALCAM. The presence of this ALCAM-Fc chimera 
was found to enhance the tubule formation capacity of 
HECV human endothelial cells, potentially indicating 
a pro-angiogenic effect, which could support advanced 
tumor growth and aid metastatic dissemination. ALCAM 
has previously been associated with the processes of 
embryonic hematopoiesis and vasculoangiogenesis and, 
somewhat in contrast to our data, a soluble ALCAM-
Fc chimera has previously been shown to negatively 
influence tube formation in yolk sac derived endothelial 
cells [37]. Soluble recombinant human ALCAM-Fc has 
also been shown to inhibit the trans-endothelial migration 
of monocytes without influencing migration or attachment 
to PMVEC endothelial cells [38]. In our current study 
ALCAM-Fc chimera also had differential effects on 
cancer cell attachment to endothelial or osteoblast cells, 
inhibiting LNCaP but not PC-3 or VCaP cell attachment. 
This may in part be due to differing cellular expression 
profiles of ALCAM within these cell lines, which could 
possibly allow for a greater disruption of ALCAM-
ALCAM interactions in these cells. However, additional 
mechanisms, receptors or binding partners may exist and 
the nature and heterogeneity of a particular cancer type 
may also be a key factor in such mechanisms.
Our current data suggests that suppression of 
ALCAM may be associated with a more aggressive cellular 
phenotype in vitro, but this appeared to be largely cell line 
specific. Many differences exist between PC-3 and LNCaP 
cells utilized in this study, with perhaps one of the more 
significant being their androgen receptor (AR) status and 
responsiveness to androgen. Such differences as well as 
others may likely account for differential results between 
the cell lines though the importance of AR or androgen was 
not directly explored in this study and requires additional 
scientific investigation. Similar observations regarding 
ALCAMs role in regulating cellular phenotype have 
been noted in a number of other studies/cancers, though 
others suggest a contrasting role for ALCAM in regulating 
such traits in vitro and in vivo [6–11]. A recent study by 
Devis et al. [8], demonstrated ALCAM suppression in 
endometrial cells could reduce migration and invasion 
in vitro and also reduce primary tumor development and 
metastatic local spread in an orthotopic model, a trait 
not associated with proliferative changes but suggested 
to arise through the influence of ALCAM in cell micro-
environment communications. Furthermore Devis et al., 
describe differences in gene profiles between control 
and ALCAM suppressed cells highlighting a number of 
pathways altered in cancer, including integrin signaling, 
as well as genes associated with motility and invasion 
[8]. ALCAM has also previously been shown to be a key 
regulator of prostate cancer dissemination to, and tumor 
development within the bone, with ALCAM suppression 
reducing skeletal metastasis and intratibial tumor growth 
but having no proliferative effects on tumor development 
within an orthotopic model implanted into the prostate 
[6]. In vitro ALCAM suppression has also been shown to 
result in a loss of TGFβ induced migration but only result 
in a non-significant increase in spontaneous migration rates 
[6]. To further explore potential mechanisms involved we 
undertook a protein microarray. Interestingly, differential 
total- or phospho-expression was seen in a number of 
receptors, signaling pathways and downstream effectors. 
This may provide a clue as to the differential in vitro and 
clinical impact of ALCAM in our study, and may suggest 
that loss of ALCAM may influence cellular traits but may 
also regulate the expression/phosphorylation of receptors 
and/or signaling pathways such as MET, a pathway 
frequently dysregulated in cancer [39], and/or other 
downstream effector pathways. However, the data presented 
is preliminary and some contrast exists between protein data 
within the micro-array and/or the quantitative transcript 
analysis. Similarly, loss or reduced expression of molecules 
such as FAK have previously been associated with a less 
aggressive cancer type and inhibition/disruption of this 
pathway as a potential therapeutic [40], rather than a more 
aggressive cellular phenotype reported here. Taken together, 
this suggests ALCAM may act as a mediator of tumor cell 
interactions with the surrounding micro-environment and 
a regulator of signal propagation within the cell, though 
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this appears to be dependent on the particular environment 
or factors present. However, additional intense study is 
required to fully explore this, focusing on validation of 
the micro-array using conventional methods, together with 
exploring the impact of ALCAM suppression in complex 
multi-cellular environments. Furthermore, our data 
provides additional relevance to the potential roles played 
by extracellular ALCAM which may impact angiogenesis 
or cell attachment at secondary sites. Together, this may 
help explain the differential, complex role of ALCAM at a 
cellular and wider clinical level and supports the dual role 
of ALCAM proposed by Hansen et al. [6]. Further intense 
work is necessary to fully elucidate these complex roles and 
the clinical potential of ALCAM.
In summary, our current data suggest that serum 
ALCAM may have promise as a prognostic indicator in 
prostate cancer. Furthermore, ALCAM may influence 
cellular traits, and also their responsiveness to external 
stimuli. Extracellular ALCAM may also contribute to 
aspects of metastatic dissemination.
MATERIALS AND METHODS
Cell lines, materials and culture conditions
PC-3, LNCaP, VCaP, CAHPV-10, PZHPV-7, 
hFOB1.19, MDA-PCa-2b and DU-145 cell lines were 
purchased from the American Type Culture Collection 
(ATCC; Middlesex, UK). Human HECV endothelial 
cells were purchased from Interlab Cell Line Collection 
(ICLC; Genoa, Italy). PC-3, LNCaP, VCaP, HECV and 
hFOB1.19 cells were used in functional assays. PC-
3, VCaP and HECV cells were grown in Dubecco’s 
Modified Eagle Medium (DMEM)/Ham’s F12 with 
L-glutamine (Sigma-Aldrich, Dorset, UK) and LNCaP 
cells were cultured in RPMI 1640 medium (Sigma-
Aldrich, Dorset, UK). Human hFOB1.19 osteoblasts 
were maintained in DMEM/Ham’s F-12 without phenol 
red (Life Technologies, Paisley, UK) containing 0.3mg/
ml G418 (Melford Laboratories, Suffolk, UK). All base 
mediums were supplemented with 10% foetal calf serum 
(FCS) (Sigma-Aldrich, Dorset, UK) and an antimicrobial 
solution (Sigma-Aldrich, Dorset, UK). Cells were cultured 
at 95% humidity, 5% CO2 and 37° C except hFOB1.19 
which were cultured at 34° C.
HGF was a kind gift from Dr T Nakamura (Osaka 
University Medical School, Japan). Recombinant human 
ALCAM, comprising a fusion of ALCAM Trp28 - Ala526 
and the human IgG Fc region (ALCAM-Fc chimera) was 
purchased from R&D systems (Abingdon, UK).
Preparation of bone matrix extract (BME) from 
femoral heads
BME was generated in house from human femoral 
heads and has been previously described [11]. Briefly, 
femoral heads, obtained immediately following hip 
replacement surgery in conjunction with ethical approval, 
were ground using a bone mill (Splerings Orthopaedics 
B. V., The Netherlands). Fine material was collected in 
balanced saline solution (BSS) and subjected to sonication 
at 4° C using a BioRuptor (Wolf Laboratories, York, UK) 
and the resulting solutions collected and stored at –80° C.
Clinical samples
A TMA comprising 48 patient samples, containing 
duplicate cores from 36 patients diagnosed with 
adenocarcinoma and duplicate (with the exception of 
1 sample, where n = 1) cores of matched normal tissue 
for 8 patients, (HPro-Ade96Sur-01) was purchased from 
Insight Biotechnologies (Middlesex, UK). Single cores 
from 4 metastatic locations were also contained on the 
array though due to the nature of these tissue types, 
namely bone section staining, were not included in the 
analysis. Where available, the median follow up period 
was 23 months.
Serum samples from prostate cancer patients were 
obtained from the Wales Cancer Bank (WCB) which 
is funded by the Wales Assembly Government and 
Cancer Research Wales. Other investigators may have 
received specimens from the same subjects. A total of 
229 samples were utilized in the study with a median 
patient age of 65 years and a median follow up period 
of 4.0 years.
Immunohistochemical staining of ALCAM in a 
prostate cancer TMA
ALCAM expression was assessed across a TMA 
of normal prostate and prostate cancer sections. TMA 
antigen retrieval was undertaken in 0.1M EDTA buffer, 
heated in a microwave for 20 minutes, allowed to cool 
under running tap water and blocked with 5–10% horse 
serum for two hours. Following blocking, the TMA was 
incubated overnight with ALCAM primary antibody (final 
concentration 2 µg/ml; Novacastra, Milton Keynes, UK) 
before incubation with secondary and tertiary reagents 
from a Vectastain Elite Universal ABC kit (Vector 
Laboratories ltd., Peterborough, UK), in accordance 
with the manufacturers guidelines, and developing with 
diaminobenzidine (5mg/ml; Sigma-Aldrich, Dorset, UK) 
for 10 minutes. Subsequently, the TMA was counterstained 
with Gill’s hematoxylin (Vector Laboratories ltd., 
Peterborough, UK), dehydrated, cleared in xylene and 
mounted in DPX (Sigma-Aldrich, Dorset, UK). Digital 
images were acquired under the microscope and epithelial 
staining intensity assessed and scored by three researchers 
as no (0), weak (1), moderate (2), or strong (3). Where 
initial conflict occurred, samples were reanalyzed and a 
consensus decision reached. Average scores for duplicate 
cores were used.
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Enzyme linked immunosorbent assay (ELISA) 
quantification of serum ALCAM
Patient serum ALCAM was detected using a human 
ALCAM (CD166) ELISA assay (Life Technologies, 
Paisley, UK) in accordance with the manufacturer’s 
guidelines and analyzed in conjunction with available 
clinicopathological information.
Generation of ALCAM suppression in prostate 
cancer cells
ALCAM specific ribozyme transgenes were 
designed, generated and cloned as described in previous 
studies [11, 41]. Plasmids were transfected into 
mammalian cells using electroporation. Both plasmids 
containing ribozyme transgenes (designated ALCAM KO) and 
control plasmids (designated pEF6) were used to transfect 
cells.
RNA extraction and reverse transcription 
polymerase chain reaction (RT-PCR)
RNA was extracted using TRI-reagent (Sigma-
Aldrich, Dorset, UK) in accordance with the 
manufacturer’s instructions. Following extraction, 
RNA was standardized and reverse transcribed using 
a high capacity cDNA reverse transcription kit (Life 
Technologies, Paisley, UK). Subsequently, polymerase 
chain reaction (PCR) was undertaken using primers 
designed to amplify Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) or ALCAM (Table 1), GoTaq 
Green Mastermix (Promega UK, Southampton, UK), 
sample cDNA and molecular biology grade water. PCR 
conditions were; initial denaturing at 94° C for 5 minutes 
followed by 32–34 cycles of 94° C for 30 seconds, 55° C 
for 30 seconds and 72° C for 40 seconds, before a final 
extension of 72° C for 10 minutes and holding at 4° C. 
Products were subsequently separated on an agarose gel 
stained with SYBR safe (Life Technologies, Paisley, UK) 
and visualized under blue light.
Quantitative polymerase chain reaction
Quantitative polymerase chain reaction (qPCR) 
was undertaken based on a previously reported technique 
[42, 43]. Briefly, reactions were prepared containing, 
PrecisionFAST qPCR mastermix (Primer Design, 
Eastleigh, UK), forward primer, z-tagged reverse primer 
(Table 1), Uniprimer probe (Intergen Inc., Oxford, UK), 
molecular biology grade water and sample cDNA and 
were run on a StepOne Plus qPCR detection system (Life 
Technologies, Paisley, UK). Reaction conditions were; 
initial 95° C for 15 minutes followed by 100 cycles of 
95° C for 15 seconds, 55° C for 35 seconds and 72° C 
for 20 seconds. Samples were run simultaneously 
with a standard of known transcript copy number, 
allowing calculation of relative transcript expression. 
Quantification of GAPDH expression was subsequently 
used to normalize samples.
Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and western 
blotting
Cells were harvested and lysed in lysis buffer for 1 
hour, on a rotating wheel at 4° C, before being centrifuged 
at 13,000g to remove insolubles, quantified using a Bio-
Rad DC protein assay kit (Bio-Rad laboratories, Hemel 
Hempstead, UK), standardized, diluted in sample buffer 
(Sigma-Aldrich, Dorset, UK) and boiled for 5 minutes. 
Samples were separated using SDS-PAGE and transferred to 
an Immobilon-P PVDF membrane (Sigma-Aldrich, Dorset, 
UK) using a semi-dry method. Membranes were probed 
using a SNAP-ID system (Merck-Millipore, Watford, 
UK) in accordance with the manufacturer’s guidelines and 
visualized using EZ-ECL reagent (GeneFlow, Lichfield, 
UK). ALCAM and GAPDH primary antibodies (Insight 
Biotechnology ltd., Middlesex, UK) and an anti-mouse HRP 
conjugated secondary antibody (Sigma-Aldrich, Dorset, 
UK) were used to detect proteins of interest.
Cell characterization assays
A range of cell characterization assays were 
performed to assess the impact of ALCAM on cellular 
functions based on previously described methods [42, 44, 
45]. Briefly, cell growth rates were assessed using an in 
vitro cell growth assay. Cells were seeded into triplicate 96 
well plates and incubated for either overnight, 3 days or 5 
days. Following incubation cells were fixed in 4% formalin 
and stained in 0.5% crystal violet before extracting stain 
with 10% acetic acid and measuring absorbance at 540nm, 
allowing the calculation of percentage growth increase 
from the overnight reference plate.
Cellular invasion was assessed using a Matrigel 
invasion assay. PC-3 and LNCaP cells were seeded into 
transwell inserts, containing 8.0µm pores, pre-coated 
with 50 µg of Matrigel (Corning, UK) suspended in a 
24 well plate containing growth media. Following 3 day 
incubation, inserts were removed and the inner chamber 
cleaned thoroughly before fixing cells on the underside of 
the insert in 4% formalin and staining with 0.5% crystal 
violet. Representative images were then captured and 
quantified under ×20 objective magnification.
A matrix adhesion assay was used to assess cellular 
attachment to Matrigel. Cells were seeded into 96 well 
plates pre-coated with 5 µg/ml Matrigel and incubated for 
45 minutes. Subsequently, wells were washed in PBS and 
adherent cells fixed in 4% formalin and stained with 0.5% 
crystal violet. Representative images were then captured 
and quantified under ×20 objective magnification.
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PC-3 cell motility was assessed using an in vitro 
cytodex-2 bead motility assay. Cells were seeded into 
10ml of growth medium containing cytodex-2 beads 
and incubated overnight. Subsequently, the beads were 
washed, pelleted and resuspended before seeding into a 
96 well plate. Following 4 hour incubation, plates were 
washed with PBS, fixed in formalin and stained with 
crystal violet. Representative images were taken, and 
quantified, of cells which had migrated to the bottom of 
the well under ×20 objective magnification.
LNCaP and HECV cell migration was assessed 
using an ECIS assay using an ECIS Zθ system and 96W1E 
96 plates (Applied Biophysics Inc., NY, USA). Cells were 
seeded and incubated to allow confluence before inducing 
a wound by applying 1400uA for 30 seconds (for LNCaP 
cells) or 3000uA for 20 seconds (for HECV cells). The 
change in resistance within each well was subsequently 
recorded and used to quantify migration.
Angiogenic potential was assessed using a Matrigel 
tubule formation assay. Briefly, 96 well plates were coated 
with 500 µg of Matrigel before seeding HECV cells and 
incubating for 4-6 hours. Tubules formed over this period 
were visualized under ×4 objective magnification and 
quantified through assessment of total tubule perimeter 
per field.
Kinexus protein microarray analysis
Differences in total and phospho-protein expression 
between PC-3pEF6 and PC-3ALCAM KO were assessed using a 
Kinexus protein microarray as previously described [46]. 
Briefly, harvested cells were resuspended and lysed in lysis 
buffer for 1 hour, on a rotating wheel at 4° C, insolubles 
removed, through centrifugation, and samples standardized 
before being sent to Kinexus Bioinformatics, Vancouver, 
Canada for analysis using a KAM-880 array. Differential 
expression between PC-3pEF6 and PC-3ALCAM KO samples 
was interrogated based on normalized signal strength and 
Z ratio.
In vitro 1,1’-Dioctadecyl-3,3,3′,3′-
Tetramethylindocarbocyanine Perchlorate (DiI) 
cell-cell interaction assays
Cell interaction/attachment was assessed in the 
presence of ALCAM-Fc chimera using a DiI staining 
technique based on a previously described method 
[47]. Briefly, HECV or hFOB1.19 cells were grown 
to confluence in a 96 well plate before seeding cancer 
cells, pre-stained with 5µM DiI for 30 minutes, onto the 
monolayer and incubating for 40 minutes. Subsequently, 
wells were washed in PBS and adherent cells fixed in 4% 
formalin. Representative bright field and TRITC images 
were captured on a Leica fluorescent inverted microscope 
(Leica Microsystems Ltd., Milton Keynes, UK) at ×20 
objective magnification, the images merged and attached 
cancer cells quantified.
Statistical analysis
Statistical analysis was undertaken using the 
SigmaPlot 11.0 (Systat Software Inc., London, UK) 
and Minitab 14 (Minitab Ltd., Coventry, UK) statistical 
software packages and data analyzed using a t-test, 
Mann Whitney test, one way ANOVA or Kruskal-Wallis 
ANOVA on RANKS with post hoc analysis. p < 0.05 
was considered to be statistically significant. ROC and 
Spearman’s rank correlation tests were used to analyze 
patient serum data.
Abbreviations
ADAM: a disintergrin and metalloprotease; 
ALCAM: activated leukocyte cell adhesion molecule; 
Table 1: Primers used in the study
Primer Forward Reverse
ALCAM (PCR) TTATCATACCTTGCCGACTT GGGTGGAAGTCATGGTATAG
ALCAM (qPCR) CAGGAGGTTGAAGGACTAAA ACTGAACCTGACCGTACAGGGATCAGTTTTCTTTGTCA
GAPDH (PCR) GGCTGCTTTTAACTCTGGTA GACTGTGGTCATGAGTCCTT




FAK (qPCR) CTATCCAGGTCAGGCATCT ACTGAACCTGACCGTACACGCAGGTCCAATACTGTAGA
AKT (qPCR) CTACTACGCCATGAAGATCC ACTGAACCTGACCGTACAGGTCTGGAAAGAGTACTTC
AG
ERK1 (qPCR) ACACGCAGTTGCAGTACA ACTGAACCTGACCGTACAGGGGCTGATCTTCTTGAT
ERK2 (qPCR) CCAACCTCTCGTACATCG ACTGAACCTGACCGTACAGGGGCTGATTTTCTTGAT
ACTGAACCTGACCGTACA represents Z sequence.
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AR: androgen receptor; BME: bone matrix extract; 
CA125: cancer antigen 125; CA15-3: cancer antigen 15-
3; CEA: carcinoembryonic antigen; ECIS: electric cell 
substratum impedance sensing; EGF: epidermal growth 
factor; ELISA: enzyme linked immunosorbent assay; 
ERK: extracellular signal regulated kinase; FAK: focal 
adhesion kinase; GAPDH: glyceraldehyde-3-phosphate 
dehydrogenase; HGF: hepatocyte growth factor; PRCa: 
prostate cancer; PSA: prostate specific antigen; ROC: 
receiver operating characteristic; TGFβ: transforming 
growth factor beta; TMA: tissue microarray.
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